ArticleJAMA network open2018
Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings.
Article in JAMA network open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 71 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 3 syntheses or guidelines pooled it, 230 citations in OpenAlex.
- From 'traditional' remedies to 'modern' supplements: a systematic review and meta-analysis of pharmaceutical adulteration in weight-loss natural products.Frontiers in pharmacology · 2025Pooled it
- Dietary Supplements for Erectile Dysfunction: Analysis of Marketed Products, Systematic Review, Meta-Analysis and Rational Use.Nutrients · 2023Pooled it
- A Systematic Review of Dietary Supplements and Alternative Therapies for Weight Loss.Obesity (Silver Spring, Md.) · 2021Pooled it
- Trial
- Article
- Review
- Fatal Yellow Oleander Poisoning From a Weight-Loss Seed Product Requiring Venoarterial Extracorporeal Membrane Oxygenation.JACC. Case reports · 2026Article
- Flavonoid Composition and Molecular Basis of the Potential Sexual-Enhancing Properties of aPharmaceuticals (Basel, Switzerland) · 2026Article
- Quantitative Analysis of the Vitamin DPharmaceuticals (Basel, Switzerland) · 2026Article
- Severe Lithium Toxicity due to the Use of Unauthorized Weight Loss Medication.Bipolar disorders · 2026Article
- Between Deficiency and Excess: The Dual Role of Selected Dietary Supplements in Immune Health.Cureus · 2026Review
- Article
- Identification of the consequences of the proliferation of counterfeit sports supplements market.BMC research notes · 2025Article
- Blood in Capsules: Multi-Technique Forensic Investigation of Suspicious Food Supplement.Molecules (Basel, Switzerland) · 2025Review
- Leader-Inspired Nutrition: Promoting Safe Dietary Supplement Use for Service Members.Nutrients · 2025Article
- Rethinking Synthetic Berberine in Nutraceuticals: Nitrosamine Risks, Regulatory Oversight, and Safer Alternatives.Molecules (Basel, Switzerland) · 2025Review
- Dietary Modulation of Metabolic Health: From Bioactive Compounds to Personalized Nutrition.Metabolites · 2025Review
- Dietary Supplement Adulteration: Laboratory Approaches to Risk Mitigation.Journal of natural products · 2025Review
- Immunoglobulin A vasculitis and pustular psoriasis precipitated by Tawon Liar: a case report.Journal of medical case reports · 2025Article
- Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Over half of adults in the United States report consuming dietary supplements. The US Food and Drug Administration (FDA) has warned of numerous dietary supplements containing undeclared, unapproved pharmaceutical ingredients. These FDA warnings have not been comprehensively analyzed for recent years. Objective: To summarize trends across adulterated (containing unapproved ingredients) dietary supplements associated with a warning released by the FDA from 2007 through 2016. Design, Setting, and Participants: In this quality improvement study, data were extracted from the FDA's Center for Drug Evaluation and Research, Tainted Products Marketed as Dietary Supplements_CDER database from 2007 through 2016. Data from each warning were recorded unless multiple warnings were issued for the same product within a 6-month period. Date, product name, company, hidden ingredient(s), product category, source of sample, and warning document type were recorded for each included warning. Data analysis was conducted from February 2017 to June 2017. Results: From 2007 through 2016, 776 adulterated dietary supplements were identified by the FDA and 146 different dietary supplement companies were implicated. Most of these products were marketed for sexual enhancement (353 [45.5%]), weight loss (317 [40.9%]), or muscle building (92 [11.9%]), with 157 adulterated products (20.2%) containing more than 1 unapproved ingredient. The most common adulterants were sildenafil for sexual enhancement supplements (166 of 353 [47.0%]), sibutramine for weight loss supplements (269 of 317 [84.9%]), and synthetic steroids or steroid-like ingredients for muscle building supplements (82 of 92 [89.1%]). There were 28 products named in 2 or 3 warnings more than 6 months apart. Of these products, 19 (67.9%) were reported to contain new unapproved ingredients in the second or third warning, consistent with the assumption that the FDA found the product to be adulterated more than once. In recent years (2014-2016), 117 of 303 adulterated samples (38.6%) were identified through online sampling and 104 of 303 (34.3%) were identified through the examination of international mail shipments. Conclusions and Relevance: Active pharmaceuticals continue to be identified in dietary supplements, especially those marketed for sexual enhancement or weight loss, even after FDA warnings. The drug ingredients in these dietary supplements have the potential to cause serious adverse health effects owing to accidental misuse, overuse, or interaction with other medications, underlying health conditions, or other pharmaceuticals within the supplement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.